Cover
Cover | Jun. 15, 2022 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A amends the Original Report to disclose that in light of the outcome of the stockholder vote and the recommendation of the Company’s Board of Directors, the Company will hold future stockholder advisory votes on the compensation of the Company’s named executive officers on an annual basis. This policy will remain in effect until the next required stockholder vote on the frequency of advisory votes on the compensation of named executive officers, which is required to occur no later than the Company’s Annual Meeting of Stockholders in 2028. |
Document Period End Date | Jun. 15, 2022 |
Entity File Number | 001-37719 |
Entity Registrant Name | CORVUS PHARMACEUTICALS, INC. |
Entity Central Index Key | 0001626971 |
Entity Tax Identification Number | 46-4670809 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 863 Mitten Road, Suite 102 |
Entity Address, City or Town | Burlingame |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94010 |
City Area Code | (650) |
Local Phone Number | 900-4520 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, Par Value $0.0001 per share |
Trading Symbol | CRVS |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |